BRCA1 and mismatch repair cancer syndrome 1: The NCCN guidelines recommended olaparib and pembrolizumab for advanced PDAC patients with germline BRCA1/2 (gBRCA) mutations and mismatch repair deficiency (dMMR)/microsatellite instability (MSI), respectively.2